Comprehensive Review and Updated Analysis of DNA Methylation in Hepatocellular Carcinoma: From Basic Research to Clinical Application

Overview

Journal Clin Transl Med

Publisher Wiley

Specialty General Medicine

Date 2024 Oct 27

PMID 39462685

Authors

Lin Su

Jiawen Bu

Jiahui Yu

Mila Jin

Guanliang Meng

Xudong Zhu

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is a primary malignant tumour, ranking second in global mortality rates and posing significant health threats. Epigenetic alterations, particularly DNA methylation, have emerged as pivotal factors associated with HCC diagnosis, therapy, prognosis and malignant progression. However, a comprehensive analysis of the DNA methylation mechanism driving HCC progression and its potential as a therapeutic biomarker remains lacking. This review attempts to comprehensively summarise various aspects of DNA methylation, such as its mechanism, detection methods and biomarkers aiding in HCC diagnosis, treatment and prognostic assessment of HCC. It also explores the role of DNA methylation in regulating HCC's malignant progression and sorafenib resistance, alongside elaborating the therapeutic effects of DNA methyltransferase inhibitors on HCC. A detailed examination of these aspects underscores the significant research on DNA methylation in tumour cells to elucidate malignant progression mechanisms, identify diagnostic markers and develop new tumour-specific inhibitors for HCC. KEY POINTS: A comprehensive summary of various aspects of DNA methylation, such as its mechanism, detection methods and biomarkers aiding in diagnosis and treatment. The role of DNA methylation in regulating hepatocellular carcinoma's (HCC) malignant progression and sorafenib resistance, alongside elaborating therapeutic effects of DNA methyltransferase inhibitors. Deep research on DNA methylation is critical for discovering novel tumour-specific inhibitors for HCC.

Citing Articles

Comprehensive review and updated analysis of DNA methylation in hepatocellular carcinoma: From basic research to clinical application.

Su L, Bu J, Yu J, Jin M, Meng G, Zhu X Clin Transl Med. 2024; 14(11):e70066.

PMID: 39462685 PMC: 11513202. DOI: 10.1002/ctm2.70066.

References

Esteller M, Corn P, Baylin S, Herman J . A gene hypermethylation profile of human cancer. Cancer Res. 2001; 61(8):3225-9. View

Li B, Cao Y, Meng G, Qian L, Xu T, Yan C . Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway. EBioMedicine. 2018; 39:239-254. PMC: 6355660. DOI: 10.1016/j.ebiom.2018.11.063. View

Norman J, Li P, Kotwani P, Shui A, Yao F, Mehta N . AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation. J Hepatol. 2023; 79(6):1469-1477. PMC: 10998694. DOI: 10.1016/j.jhep.2023.08.020. View

Kuang Y, El-Khoueiry A, Taverna P, Ljungman M, Neamati N . Guadecitabine (SGI-110) priming sensitizes hepatocellular carcinoma cells to oxaliplatin. Mol Oncol. 2015; 9(9):1799-814. PMC: 5528722. DOI: 10.1016/j.molonc.2015.06.002. View

Wallace M, Preen D, Jeffrey G, Adams L . The evolving epidemiology of hepatocellular carcinoma: a global perspective. Expert Rev Gastroenterol Hepatol. 2015; 9(6):765-79. DOI: 10.1586/17474124.2015.1028363. View

Hsiao C, Lu C, Su H, Huang K . Plasma Cell-Free Adenomatous Polyposis Coli Gene Promoter Methylation as a Prognostic Biomarker for Hepatocellular Carcinoma. Oncology. 2024; 102(11):935-943. PMC: 11548096. DOI: 10.1159/000538455. View

Fang X, Yan Q, Liu S, Guan X . Cancer Stem Cells in Hepatocellular Carcinoma: Intrinsic and Extrinsic Molecular Mechanisms in Stemness Regulation. Int J Mol Sci. 2022; 23(20). PMC: 9604119. DOI: 10.3390/ijms232012327. View

Bai Y, Tong W, Xie F, Zhu L, Wu H, Shi R . DNA methylation biomarkers for diagnosis of primary liver cancer and distinguishing hepatocellular carcinoma from intrahepatic cholangiocarcinoma. Aging (Albany NY). 2021; 13(13):17592-17606. PMC: 8312421. DOI: 10.18632/aging.203249. View

Sen N, Gui B, Kumar R . Role of MTA1 in cancer progression and metastasis. Cancer Metastasis Rev. 2014; 33(4):879-89. PMC: 4245458. DOI: 10.1007/s10555-014-9515-3. View

10.

Pasha H, Mohamed R, Radwan M . RASSF1A and SOCS1 genes methylation status as a noninvasive marker for hepatocellular carcinoma. Cancer Biomark. 2019; 24(2):241-247. DOI: 10.3233/CBM-181638. View

11.

Reister S, Kordes C, Sawitza I, Haussinger D . The epigenetic regulation of stem cell factors in hepatic stellate cells. Stem Cells Dev. 2011; 20(10):1687-99. DOI: 10.1089/scd.2010.0418. View

12.

Mizuno Y, Maemura K, Tanaka Y, Hirata A, Futaki S, Hamamoto H . Expression of delta-like 3 is downregulated by aberrant DNA methylation and histone modification in hepatocellular carcinoma. Oncol Rep. 2018; 39(5):2209-2216. DOI: 10.3892/or.2018.6293. View

13.

Deng Z, Ji Y, Han B, Tan Z, Ren Y, Gao J . Early detection of hepatocellular carcinoma via no end-repair enzymatic methylation sequencing of cell-free DNA and pre-trained neural network. Genome Med. 2023; 15(1):93. PMC: 10631027. DOI: 10.1186/s13073-023-01238-8. View

14.

Li H . Intercellular crosstalk of liver sinusoidal endothelial cells in liver fibrosis, cirrhosis and hepatocellular carcinoma. Dig Liver Dis. 2021; 54(5):598-613. DOI: 10.1016/j.dld.2021.07.006. View

15.

Huang G, Wang C, Fu X . Bidirectional deep neural networks to integrate RNA and DNA data for predicting outcome for patients with hepatocellular carcinoma. Future Oncol. 2021; 17(33):4481-4495. DOI: 10.2217/fon-2021-0659. View

16.

Zhang Y, Tang B, Song J, Yu S, Li Y, Su H . Lnc-PDZD7 contributes to stemness properties and chemosensitivity in hepatocellular carcinoma through EZH2-mediated ATOH8 transcriptional repression. J Exp Clin Cancer Res. 2019; 38(1):92. PMC: 6381703. DOI: 10.1186/s13046-019-1106-2. View

17.

Chen R, Xie R, Meng Z, Ma S, Guan K . STRIPAK integrates upstream signals to initiate the Hippo kinase cascade. Nat Cell Biol. 2019; 21(12):1565-1577. DOI: 10.1038/s41556-019-0426-y. View

18.

Metaxas G, Tsiambas E, Marinopoulos S, Adamopoulou M, Spyropoulou D, Falidas E . DNA Mismatch Repair System Imbalances in Breast Adenocarcinoma. Cancer Diagn Progn. 2023; 3(2):169-174. PMC: 9949550. DOI: 10.21873/cdp.10197. View

19.

Meunier L, Hirsch T, Caruso S, Imbeaud S, Bayard Q, Roehrig A . DNA Methylation Signatures Reveal the Diversity of Processes Remodeling Hepatocellular Carcinoma Methylomes. Hepatology. 2021; 74(2):816-834. DOI: 10.1002/hep.31796. View

20.

Kaur D, Lee S, Goldberg D, Spix N, Hinoue T, Li H . Comprehensive Evaluation of The Infinium Human MethylationEPIC v2 BeadChip. Epigenetics Commun. 2024; 3(1). PMC: 10919401. DOI: 10.1186/s43682-023-00021-5. View